These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 4921174)
1. The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease. Fine EW; Lewis D; Villa-Landa I; Blakemore CB Br J Psychiatry; 1970 Aug; 117(537):157-61. PubMed ID: 4921174 [No Abstract] [Full Text] [Related]
2. Cyclandelate in long standing cerebral arteriosclerosis. Rogers WF; Shaikh VA; Clark AN Gerontol Clin (Basel); 1970; 12(2):88-93. PubMed ID: 4987660 [No Abstract] [Full Text] [Related]
3. Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate. Young J; Hall P; Blakemore C Br J Psychiatry; 1974 Feb; 124(579):177-80. PubMed ID: 4596673 [No Abstract] [Full Text] [Related]
4. Cerebral vasodilators. Hall P Br Med J; 1971 Aug; 3(5770):374. PubMed ID: 5558206 [No Abstract] [Full Text] [Related]
5. Vasodilators in geriatric psychiatry. Birkett DP J Med Soc N J; 1971 Aug; 68(8):619-23. PubMed ID: 4939868 [No Abstract] [Full Text] [Related]
6. Effect of cyclandelate on dementia. Westreich G; Alter M; Lundgren S Stroke; 1975; 6(5):535-8. PubMed ID: 1101457 [TBL] [Abstract][Full Text] [Related]
8. The use of cyclandelate in chronic brain syndrome with arteriosclerosis. Fine EW Curr Ther Res Clin Exp; 1971 Sep; 13(9):568-74. PubMed ID: 5000458 [No Abstract] [Full Text] [Related]
9. The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency. Smith WL; Lowrey JB; Davis JA Curr Ther Res Clin Exp; 1968 Dec; 10(12):613-8. PubMed ID: 4972756 [No Abstract] [Full Text] [Related]
10. A preliminary study of the effects of cyclandelate. Davies G Med J Aust; 1971 Feb; 1(6):313-7. PubMed ID: 4925923 [No Abstract] [Full Text] [Related]
11. Cyclandelate in the treatment of cerebral arteriosclerosis. Hall P J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704 [TBL] [Abstract][Full Text] [Related]
12. Clinical effects of Cyclospasmol in patients affected by chronic cerebrovascular disorders. Albizzati MG; Bassi S; Sbacchi M; Frattola L Br J Clin Pract Suppl; 1984; 34():69-73. PubMed ID: 6430327 [No Abstract] [Full Text] [Related]
13. Cyclandelate and mental functions: a double-blind cross-over trial in normal elderly subjects. Judge TG; Urquhart A; Blakemore CB Age Ageing; 1973 May; 2(2):121-4. PubMed ID: 4591604 [No Abstract] [Full Text] [Related]
14. Electroencephalographic study of dose-response relations for cyclandelate on hyperventilation-induced vasospasm in human brain. Korenyi C; Whittier JR Angiology; 1969 Oct; 20(9):529-34. PubMed ID: 5824354 [No Abstract] [Full Text] [Related]
15. Multifocal infarct dementia treated by cyclandelate and monitored by quantitative EEG. Harding GF; Hall P; Young J; Smith GA Angiology; 1978 Feb; 29(2):139-40. PubMed ID: 347986 [No Abstract] [Full Text] [Related]
16. [Clinical double blind study of a geriatric combination, UCB 8262 or Geratar]. Paquay J; Arnould F; Burton P; Piersotte J; Puffet E; Tinant M Acta Neurol Psychiatr Belg; 1965 Sep; 65(9):711-9. PubMed ID: 4954635 [No Abstract] [Full Text] [Related]
17. Protective action of cyclandelate in hypoxia. Funcke AB; van Beek MC; Nijland K Curr Med Res Opin; 1974; 2(1):37-42. PubMed ID: 4842317 [No Abstract] [Full Text] [Related]
18. [Effect of the mandelic ester of 3,5,5-trimethyl-cyclohexanol (Cyclospasmol) on blood flow potentials in peripheral obstructive arteriopathies]. Russo A; Azzolina P; Biondi M; Montemagno S; Giovinetto A Minerva Med; 1969 Aug; 60(69):3110-6. PubMed ID: 5824709 [No Abstract] [Full Text] [Related]
19. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia. Albizzati MG; Bassi S; Calloni E; Sbacchi M; Piolti R; Frattola L Drugs; 1987; 33 Suppl 2():90-6. PubMed ID: 3304956 [TBL] [Abstract][Full Text] [Related]